173 related articles for article (PubMed ID: 24786483)
1. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
5. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel.
Zhang B; Xue A; Zhang C; Yu J; Chen W; Sun D
Pharmazie; 2016 Jun; 71(6):320-6. PubMed ID: 27455550
[TBL] [Abstract][Full Text] [Related]
6. [In situ rat intestine absorption of paclitaxel-loaded solid lipid nanoparticles modified with cell-penetrating peptides].
Li CC; Zhang ZH; Zhang YL; Lü HX; Zhou JP
Yao Xue Xue Bao; 2013 Jan; 48(1):131-7. PubMed ID: 23600154
[TBL] [Abstract][Full Text] [Related]
7. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
[TBL] [Abstract][Full Text] [Related]
8. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
9. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
Lee K; Chae SW; Xia Y; Kim NH; Kim HJ; Rhie S; Lee HJ
Eur J Pharmacol; 2014 Jan; 723():381-8. PubMed ID: 24252806
[TBL] [Abstract][Full Text] [Related]
10. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
11. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.
Griffin BT; O'Driscoll CM
Pharm Res; 2008 May; 25(5):1125-33. PubMed ID: 17975709
[TBL] [Abstract][Full Text] [Related]
12. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer.
Liu J; Meisner D; Kwong E; Wu XY; Johnston MR
Cancer Res; 2009 Feb; 69(3):1174-81. PubMed ID: 19176391
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.
Roger E; Lagarce F; Garcion E; Benoit JP
Eur J Pharm Sci; 2010 Aug; 40(5):422-9. PubMed ID: 20438839
[TBL] [Abstract][Full Text] [Related]
14. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
15. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
16. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
Ganta S; Devalapally H; Amiji M
J Pharm Sci; 2010 Nov; 99(11):4630-41. PubMed ID: 20845461
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.
Zabaleta V; Ponchel G; Salman H; Agüeros M; Vauthier C; Irache JM
Eur J Pharm Biopharm; 2012 Aug; 81(3):514-23. PubMed ID: 22516136
[TBL] [Abstract][Full Text] [Related]
18. The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients.
Akhtar N; Ahad A; Khan MF; Allaham A; Talegaonkar S
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):191-199. PubMed ID: 27016067
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of paclitaxel by solid dispersion granulation.
Shanmugam S; Im HT; Sohn YT; Kim YI; Park JH; Park ES; Woo JS
Drug Dev Ind Pharm; 2015; 41(11):1864-76. PubMed ID: 25775012
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Porter CJ; Charman SA; Charman WN
J Pharm Sci; 1996 Apr; 85(4):351-6. PubMed ID: 8901067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
